Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform.

Cell reports - 25 Jun 2024

Dorighi Kristel M, Zhu Anqi, Fortin Jean-Philippe, Hung-Hao Lo Jerry, Sudhamsu Jawahar, Wendorff Timothy J, Durinck Steffen, Callow Marinella, Foster Scott A, Haley Benjamin

Abstract excerpt

Personalized cancer therapeutics bring directed treatment options to patients based on their tumor's genetic signature. Unfortunately, tumor genomes are remarkably adaptable, and acquired resistance through gene mutation frequently occurs. Identifying mutations that promote resistance within drug-treated patient populations can be cost, resource, and time intensive. Accordingly, base editing, enabled by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gene Editing

Share to Mutagenesis

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38838224
DOI: 10.1016/j.celrep.2024.114313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform.PMID 38838224Read ↗

Accelerated drug resistant variant discovery with an enhanced, scalable mutagenic base editor platformSemantic proximity Read ↗

Towards optimizing diversifying base editors for high-throughput studies of single- nucleotide variantsSemantic proximity Read ↗

Massively parallel assessment of human variants with base editor screens.Semantic proximity Read ↗

Uncovering functional variants using a high-efficiency PE3-based screening platform.Semantic proximity Read ↗

Benchmarking of SpCas9 variants enables deeper base editor screens of <i>BRCA1</i> and <i>BCL2</i>Semantic proximity Read ↗

A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects.Semantic proximity Read ↗

Rapid customization of base editors via machine learning-powered combinatorial mutagenesis.Semantic proximity Read ↗

Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activitySemantic proximity Read ↗

Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editingSemantic proximity Read ↗

Massively parallel assessment of human variants with base editor screensSemantic proximity Read ↗

Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomesSemantic proximity Read ↗

Base editing: advances and therapeutic opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.